Giving Compass' Take:

• Diane Mapes reports on the progress of ovarian cancer research, specifically the hunt for better early detection, improved outcomes, and even a future cure.

• New biomarkers and advancements in immunotherapy treatment are two key components of this battle, but more resources and funding for research are needed.

• Learn how philanthropy can make an impact in this area and other cancer fights.

Despite its long-standing nickname, ovarian cancer isn’t really a silent killer. There are symptoms; it’s just that they whisper or are commonly mistaken for something else, like aging or irritable bowel syndrome. As a result of this — and the lack of therapies for advanced disease — ovarian cancer continues to kill nearly 15,000 women a year in the U.S., most of whom are diagnosed at a late stage.

There's been recent progress in treatment: Three new targeted drugs called PARP inhibitors have helped many ovarian patients, especially those with inherited BRCA1 or BRCA2 mutations, which account for about 15 percent of all ovarian cancers. Combinations of old and new drugs have also shown promising results.

But there is much left to do to catch and squelch this killer.

Researchers at Fred Hutchinson Cancer Research Center are on the case, primarily in three of ovarian cancer’s most problematic realms: early detection and screening; differentiating the patients who won’t respond to standard chemotherapies from those who will; and developing new treatments, like immunotherapies, to beat back advanced disease.

Read the full article about squelching ovarian cancer by Diane Mapes at Fred Hutchinson Cancer Research Center.